PAPER Fan FC, Liu LM, Guo M, Du Y, Chen YW, Loh YP, Cheng Y

Neurotrophic factor-α1/carboxypeptidase E controls progression and reversal of Alzheimer's disease pathogenesis in mice.

Theranostics. 2025;15(6):2279-2292. Epub 2025 Jan 13 PubMed.

PAPER Jones RM, DeRuiter RM, Deshmukh M, Dayton PA, Pinton GF

Non-invasive volumetric ultrasound localization microscopy detects vascular changes in mice with Alzheimer's disease.

Theranostics. 2025;15(3):1110-1121. Epub 2025 Jan 1 PubMed.

PAPER Park M, Ryu H, Heo S, Kim B, Park J, Lim KH, Han SB, Park H

Targeted demethylation of cathepsin D via epigenome editing rescues pathology in Alzheimer's disease mouse model.

Theranostics. 2025;15(2):428-438. Epub 2025 Jan 1 PubMed.

PAPER Xiong W, She W, Liu Y, Zhou H, Wang X, Li F, Li R, Wang J, Qin D, Jing S, Duan X, Jiang C, Xu C, He Y, Wang Z, Ye Q

Clinical-grade human dental pulp stem cells improve adult hippocampal neural regeneration and cognitive deficits in Alzheimer's disease.

Theranostics. 2025;15(3):894-914. Epub 2025 Jan 1 PubMed.

PAPER Heidelbaugh JJ, Kim AH, Chang R, Walker PC

Overutilization of proton-pump inhibitors: what the clinician needs to know.

Therap Adv Gastroenterol. 2012 Jul;5(4):219-32. PubMed.

PAPER Waldum H, Martinsen TC

Chronic diseases: what about infections of virus and prions via the gut?

Therap Adv Gastroenterol. 2021;14:17562848211028805. Epub 2021 Sep 28 PubMed.

PAPER Nieoullon A

[Cellular bases of neurodegenerative processes].

Therapie. 1998 Jan-Feb;53(1):21-9. PubMed.

PAPER Buée L

[Cerebrovascular aging].

Therapie. 1999 Jan-Feb;54(1):155-65. PubMed.

PAPER Schück S, Bentué-Ferrer D, Beaufils C, Polard E, Belliard S, Allain H

[Adverse effects and drugs for Alzheimer's disease].

Therapie. 1999 Mar-Apr;54(2):237-42. PubMed.

PAPER Pairet M, Netter P

[Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].

Therapie. 1999 Jul Aug;54(4):433-45. PubMed.

PAPER Larousse C, Veyrac G

[Clinical data on COX-1 and COX-2 inhibitors: what possible alerts in pharmacovigilance?].

Therapie. 2000 Jan-Feb;55(1):21-8. PubMed.

PAPER Tringali G, Dello Russo C, Preziosi P, Navarra P

Interleukin-1 in the central nervous system: from physiology to pathology.

Therapie. 2000 Jan-Feb;55(1):171-5. PubMed.

PAPER Anglès A, Bagheri H, Saivin S, Montastruc JL

Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.

Therapie. 2002 Jul-Aug;57(4):408-10. PubMed.

PAPER Lestage P, Lockhart B, Roger A

[In vivo exploration of cerebral ischemia: use of neuroprotective agents in animal studies].

Therapie. 2002 Nov-Dec;57(6):554-63. PubMed.

PAPER Geerts H

[The virtual synapse what is its contribution to understanding cholinergic neural transmission?].

Therapie. 2004 Jan-Feb;59(1):21-3. PubMed.